Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 228

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 228
---
 be filed any registration statement with the Commission relating
to the offering of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our
capital stock; (c) complete any offering of our debt securities, other than entering into a line of credit with a traditional bank or
(d) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership
of our capital stock, whether any such transaction described in clause (a), (b), (c) or (d) above is to be settled by delivery of shares
of our capital stock or such other securities, in cash or otherwise. We agree to file a customary universal shelf registration statement
within 30 days of the earlier of (i) the expiration of the restricted period described above and (ii) the date of its initial eligibility
to do so. Additionally, we agree that for a period of 24 months after the offering we will not directly or indirectly offer to sell, sell,
contract to sell, grant any option to sell or otherwise dispose of shares of our capital stock or any securities convertible into or exercisable
or exchangeable for shares of our capital stock in any “at-the-market”, continuous equity or variable rate transaction, without
the prior written consent of the Representative.

Right of First Refusal

We will grant the
Representative a right of first refusal, for a period of 36 months from the closing of the offering, to act as sole investment
banker, sole book-runner and/or sole placement agent, at the Representative’s sole discretion, for each and every future
public and private equity and debt offering, including all equity linked financings, during such 36-month period, for us, or any
successor to or any subsidiary of us, on terms customary for the Representative. The Representative will have the sole right to
determine whether any other broker-dealer shall have the right to participate in any such offering and the economic terms of any
such participation. any other broker-dealer shall have the right to participate in any such offering and the economic terms of any
such participation.

<div align='center'>138</div>

Pricing of the Offering

Prior to this offering, there
was no established public market for our Ordinary Shares. The public offering price will be negotiated between us and the underwriters.
In determining the price, we will consider our history and prospects, our business potential and earnings prospects, an assessment of